Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? (Q43248406)

17 November 2017

Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? (English)

1 reference

17 November 2017

1 reference

Ann M Philbrick

1

1 reference

17 November 2017

Michael E Ernst

2

1 reference

17 November 2017

Deanna L McDanel

3

1 reference

17 November 2017

Mary B Ross

4

1 reference

17 November 2017

Kevin G Moores

5

1 reference

17 November 2017

1 November 2009

1 reference

American Journal of Health-System Pharmacy

17 November 2017

1 reference

17 November 2017

66

1 reference

17 November 2017

22

1 reference

17 November 2017

2017-2023

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

17 November 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Contraindications to the use of metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Lactic acidosis in biguanide-treated diabetics: a review of 330 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Contraindications to metformin therapy in patients with NIDDM

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Metformin and lactic acidosis: guilt by association?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Severe Acidosis in a Patient With Type 2 Diabetes Mellitus, Hypertension, and Renal Failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

A risk-benefit assessment of metformin in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Lactic acidosis rates in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Metformin and lactic acidosis: cause or coincidence? A review of case reports

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Role of metformin accumulation in metformin-associated lactic acidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Contraindications to metformin therapy among patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Contra-indications to metformin therapy are largely disregarded

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

Monitoring renal function and limitations of renal function tests

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080330

31 March 2020

Identifiers

DOI

10.2146/AJHP080330

1 reference

17 November 2017

1 reference